Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from LLY

Check Out What Whales Are Doing With LLY

A whale with a lot of money to spend has taken a noticeably bearish stance on Eli Lilly. Looking at options history for Eli Lilly (NYSE:LLY) we detected 22 strange trades.

Benzinga

Looking At Eli Lilly's Recent Whale Trades

A whale with a lot of money to spend has taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli Lilly (NYSE:LLY) we detected 15 strange trades.

Benzinga

Check Out What Whales Are Doing With LLY

Someone with a lot of money to spend has taken a bearish stance on Eli Lilly (NYSE:LLY). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Eli Lilly Whale Trades Spotted

Benzinga

Eli Lilly Whale Trades Spotted

A whale with a lot of money to spend has taken a noticeably bearish stance on Eli Lilly. Looking at options history for Eli Lilly (NYSE:LLY) we detected 21 strange trades.

Benzinga

What Are Whales Doing With Eli Lilly

A whale with a lot of money to spend has taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli Lilly (NYSE:LLY) we detected 10 strange trades.

Benzinga

Eli Lilly Whale Trades Spotted

A whale with a lot of money to spend has taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli Lilly (NYSE:LLY) we detected 15 strange trades.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Eli Lilly Whale Trades For August 11

Benzinga

What Are Whales Doing With Eli Lilly

A whale with a lot of money to spend has taken a noticeably bearish stance on Eli Lilly. Looking at options history for Eli Lilly (NYSE:LLY) we detected 11 strange trades.

Benzinga

2 Stocks That Could Be Long-Term Winners for Investors

With the economy reporting two consecutive quarters of GDP decline, many analysts believe that the economy has already entered a recession. During periods of market uncertainty, investors should look for stocks that could win in the long run based on their strong fundamentals and solid growth prospects. We think Pfizer…

StockNews.com

3 Dividend-Paying Stocks to Consider During a Recession

Rising inflation, the Fed’s hawkish stance to tame it, and an economic contraction for two consecutive quarters have stoked fears of a recession in the U.S. economy. Amid the likely economic downturn, investors could consider investing in stocks that provide a steady income in the form of dividends. Therefore, we…

StockNews.com

Is Biotech Ready for Another Bull Run? 3 Stocks to Get in Ahead of the Crowd

The biotech industry flourished during the height of the COVID-19 pandemic and reported record revenues and earnings last year. Despite the market slowdown, the sector is poised for another bull run, given the continued global fight against COVID-19 and the increasing demand with an aging population. Popular biotech stocks Pfizer…

StockNews.com

2 Biotech Stocks Crushing It During the Market Crash

The Biotech industry has gained significant momentum since the pandemic. Moreover, the industry’s prospects look bright amid the lucrative federal funding and solid investments in breakthrough developments. Thus, given the stock market volatility, it could be wise to invest in quality biotech stocks Eli Lilly (LLY) and Jazz Pharmaceuticals (JAZZ),…

StockNews.com

What Are Whales Doing With Eli Lilly

A whale with a lot of money to spend has taken a noticeably bearish stance on Eli Lilly. Looking at options history for Eli Lilly (NYSE:LLY) we detected 14 strange trades.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

If You Invested $100 In This Stock 5 Years Ago, You Would Have $400 Today

Eli Lilly (NYSE:LLY) has outperformed the market over the past 5 years by 21.93% on an annualized basis producing an average annual return of 31.32%. Currently, Eli Lilly has a market capitalization of $307.03 billion.

Benzinga

This Is What Whales Are Betting On Eli Lilly

A whale with a lot of money to spend has taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli Lilly (NYSE:LLY) we detected 17 strange trades.

StockNews.com

LLY's New Drug Lineup Looks Promising For Investors

Eli Lilly and Company’s (LLY) new drug line-up is expected to generate higher revenues and earnings. Also, LLY’s robust earnings, favorable analyst estimates, and higher-than-industry profitability make it a promising investment option. Read on….

StockNews.com

5 Stocks Upgraded To "Strong Buy" Last Week

Investors’ concerns over the impending interest rate hikes are expected to keep the markets highly volatile in the near term. Therefore, it could be wise to invest in fundamentally-sound stocks Group 1 Automotive (GPI), Eli Lilly and Company (LLY), nVent Electric (NVT), Primo Water (PRMW), and Sanmina (SANM) that are…

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

If You Invested $1000 In This Stock 15 Years Ago, You Would Have $5,000 Today

Eli Lilly (NYSE:LLY) has outperformed the market over the past 15 years by 5.21% on an annualized basis producing an average annual return of 11.42%. Currently, Eli Lilly has a market capitalization of $273.33 billion.

Benzinga

Looking At Eli Lilly's Recent Whale Trades

A whale with a lot of money to spend has taken a noticeably bearish stance on Eli Lilly. Looking at options history for Eli Lilly (NYSE:LLY) we detected 35 strange trades.

StockNews.com

3 Growth Stocks to Buy if You Think Inflation Has Peaked

A slightly lower consumer price index in April and expectations of a flat or lower CPI in May indicate inflation may have peaked. Yesterday, the major U.S. stock indices increased slightly as leading growth stocks rallied. Given this backdrop, we think it could be wise to invest in the shares…

Benzinga

In Eli Lilly's Lebrikizumab Atopic Dermatitis Study, Majority Of Patients Maintained Skin Clearance At One Year

Eli Lilly And Co (NYSE:LLY) announced topline results from one-year analyses of the efficacy and safety of lebrikizumab for moderate-to-severe atopic dermatitis (AD). The new findings from the Phase 3 trials (ADvocate 1 and 2) showed that 8/10 of patients who achieved clinical response with lebrikizumab monotherapy at 16 weeks maintained skin clearance…

Benzinga

Eli Lilly Presents New Analyses On Tirzepatide Injection For Type 2 Diabetes

Eli Lilly And Co (NYSE:LLY) presented new data from a mechanism of action study and new analyses of the global registration program for Mounjaro (tirzepatide) injection at the American Diabetes Association. At 28 weeks, participants taking Mounjaro (N=45) had significantly greater reductions in weight and fat mass compared to Novo Nordisk A/S's (NYSE:NVO) injectable Ozempic…

Benzinga

Looking At Eli Lilly's Recent Whale Trades

Benzinga

Lilly Touts Encouraging Mirikizumab Data In Ulcerative Colitis Maintenance Setting

Eli Lilly And Co (NYSE:LLY) announced a data readout for the Lucent-2 Phase 3 study of mirikizumab after 52 weeks. The trial enrolled patients with ulcerative colitis who had initially responded to mirikizumab in a 12-week Lucent-1 study. The primary endpoint was clinical remission, with 49.9% of participants in the mirikizumab arm reaching…

1 … 10 11 12 13

People

Dipanjan BanchurSince

722 stories

Mounjaro

38 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

BristolMyers Squibb Company

95 stories

ADSK

93 stories

European Medicines Agency

76 stories

Medical – Pharmaceuticals

69 stories

Johnson

63 stories

Eli Lilly and Company

58 stories

Eli Lilly And Co

54 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.